The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.
Pointers With Portela: Pre-Teen Skin Care Routine
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
The Importance of Understanding Inflammatory Markers
The Cutaneous Connection: Pearls for Atopic Dermatitis in College-Aged Patients
Pure Hypercholesterolemia and Psoriasis Share a Causal Link, Study Says
Vitiligo Case Report: A 9-Year Old Patient With White Macules, Halo Nevus